STOCK TITAN

Vor Biopharma (VOR) DEF 14A Filings

VOR NASDAQ

Here are the DEF 14A proxy statements from Vor Biopharma Inc. (VOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.

Rhea-AI Summary

Vor Biopharma Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 9:00 a.m. Eastern Time. Holders of common stock at the April 15, 2026 record date may vote online or by proxy.

Stockholders will elect two Class II directors, Fouad Namouni and Andrew Levin, for terms running to the 2029 meeting, consider an amendment and restatement of the 2021 Equity Incentive Plan, and ratify Ernst & Young LLP as independent auditor for 2026. The amended plan keeps a 4% annual “evergreen” share increase but bases it on both common shares outstanding and shares issuable upon exercise of pre-funded warrants, and adds full vesting on death for time-based awards held by employees unless an award agreement provides otherwise.